SUBJECT INDEX

A

A 23187
  at muscarinic receptor, 130
  and vasodilation, 180–81, 185, 187–89, 191–93
Abbott 47844
  inotropic effects of, 288
Acebutolol
  on renal hypertension, 110, 112–14
Acetylcholine
  in arterial relaxation, 176–79, 181, 185–94
    characteristics of, 177–79
    release of EDRF, 179
    requirement for endothelial cells, 176–77
  on membrane fluidity, 47
  at muscarinic receptor, 128–30
  rate-controlled delivery system for, 209–10
Acrylamide
  neurotoxicity of, 427–28, 432, 436, 443
ACTH
  non-equilibrium behavior of, 259
ACTH-related peptide
  chronic infusion of, 211
Actomyosin ATPases
  and vanadium, 509
Adenosine diphosphate (ADP)
  and vasodilation, 180–81
Adenosine triphosphate
  and vasodilation, 180–81
Adenylate cyclase
  at neuronal muscarinic receptor, 122
Adenyl cyclase
  and vanadium, 510–11
Adrenal medulla
  developmental studies of, 68–69
Adrenergic nervous system
  ontogeny of, 66–68
    heart, 67–68
β-Adrenergic receptors
  developmental studies of, 67, 72–73
Adrenergics
  and inotropic agents, 275–78
    activity loss after prolonged administration, 277–78
    separation of inotropic and chronotropic effects, 276–77
Adrenergic transmitter-releasing agents
  inotropic effects, 289–90
β-Adrenoceptor antagonists (β-blockers)
  in renal hypertension, 109–12
    acute parenteral β-blockade, 110–11
    chronic oral β-blockers, 111–12
Adrenoceptors
  and positive inotropics, 275–78
α-Adrenoceptors
  and renal hypertension, 106–9
  agonists, 106–8
  antagonists, 108–9
Adriamycin
  immunomodulation by, 152
α and β Agonists
  tolerance studies, 212, 223
Air pollution
  cyanide in, 453
Alcohols
  in membranes, 46–47, 51–59
    aliphatic, 51–52, 54, 56
    benzyl, 51
  teratogenic effects of, 487–88
Aldicarb
  metabolism of, 31
Aldosterone
  delivery systems in study of, 214
Aldrin
  metabolism of, 20–21, 24–25, 27, 34, 36
    in fish and birds, 20–21
Alkanols
  on membrane fluidity, 51, 54, 56
Alkenols
  on membrane fluidity, 52
Alkylleads
  neurotoxicity of, 429
Alkyltins
  neurotoxicity of, 443
Allelopathics
  reviews of, 526
Allopurinol
  inotropic effects of, 306
Allosteric principle
  solvent entropy, hydrophobic effect, and macromolecular stability, 238–40
Alprenol
  modulated receptor hypothesis, 391
Alprostadil
  delivery systems for, 200
Alzheimer's disease
  potential drug therapy for, 123
Ameziniumetil sulfate (LU 1631)
  inotropic effects of, 290
  structure, 290
Amino acids
  rate-controlled delivery systems for, 208–9, 218
5-Amino-[3,4'-bipyridine]-6-one
  see Amrinone
Aminoethanol
  inotropic effects of, 306
Aminopterin
  teratogenic effects of, 487–88
Aminotetrahydrocarbazole
  inotropic effects of, 290
  structure of, 290
Amiodarone
  modulated receptor hypothesis, 389, 391–92, 397–99, 401, 411
Amphetamine
  non-equilibrium behavior of, 260
D-Amphetamine
  tolerance studies, 212
Amrinone (Win 40680)
  and inotropism, 284, 291, 294–95
  structure, 291
Amygdalin (laetrile)
  cyanide poisoning from, 454
Amyl nitrite
  cyanide antagonism by, 462, 464
Analgetics
  central, monograph of, 530–31
Androgens
  teratogenic effects of, 487–88, 490
Andromedotoxins
  inotropic effects of, 303
Anemonia sulcata
  inotropic substance from, 303–4
Anesthestics
  on membrane fluidity, 48–50, 54–56
Anesthetics, local
  and antiarrhythmics, 403
  at muscarinic receptors, 123
Angiotensin
  developmental studies of, 74

Angiotensin II
delivery systems for, 199–200, 212–14, 225
and vasodilation, 178
Anoxia
on arterial relaxation, 185
Anthopleura xanthogrammica
inotropic effects of, 303–5
Anthopleurin-A
inotropic effects of, 303–5
Antiadrenergics
in renal hypertension, 105–20
at α-adrenoceptors, 106–9
β-adrenoceptor antagonists, 109–12
introduction, 105–6
pathophysiology of variable effects of, 112–17
summary, 117
Antiarrhythmics
modulated receptor hypothesis, 387–412
applications of, 409–12
calcium channel blockade, 405–9
explanation of, 388–89
introduction, 387–88
sodium channel blockers, 389–405
Antibiotics
combined, 527
Anticholinergics
and neuroleptics, 367–73
Antidepressants
at muscarinic receptor, 123
and vanadium, 513
Antigens
specific immunotherapy, 151–54
Antihypertensives
rational basis for, 527
rebound studies, 223–24
Anti-juvenoids
metabolism of, 33
Antipsychotics
plasma neuroleptic monitoring, 361–80
Antithyroid drugs
teratogenic effects of, 489, 494–95
AP 10
inotropic effects of, 290
structure of, 290
Apricots
cyanide intoxication from, 453
Aprindine
modulated receptor hypothesis, 391, 409
AQA-39
modulated receptor hypothesis, 409
Arachidonic acid
on arterial relaxation, 183–185, 191
Arene oxide
in insecticide metabolism, 26
in PCB metabolism, 89
Aroclor 1248
pharmacokinetics of, 85, 88, 92
Aroclor 1254
metabolism of, 34
Arsenic
neurotoxicity of, 431, 436, 443
Artery
relaxation of, 175–94
Ascorbate
vanadium effects on, 506
ASL 7022
inotropic effects of, 280, 288
structure, 280
Assessment
of neurobehavioral toxicity, 425–46
Atenolol
on renal hypertension, 110–15
Atropine
developmental studies with, 95
ATX 11
inotropic effects of, 303–4
Axepexole
delivery systems in rebound study, 223
Azimexon
immunomodulation by, 152

B

Bacillus Calmette-Guerin (BCG)
immunomodulation by, 152, 159–61
Bamboo shoot
cyanide intoxication from, 453
Banol
metabolism of, 26
Barbiturates
on membrane fluidity, 50–51, 54, 56
Barium
at muscarinic receptor, 128
Batrachotoxins
inotropic effects of, 302
structure of, 303
BAYK 8644
inotropic effects of, 307
modulated receptor hypothesis, 407
Behavior
and toxicity
assessment considerations, 425–46
Benzocaine
modulated receptor hypothesis, 391–93, 398, 411
Benzodiazepines
on membrane fluidity, 44
Benzofuranylethanolamine
inotropic effects of, 290
structure, 290
Benzyl alcohol
and membrane fluidity, 51, 54
Benzylaminodihydrodimethoxyimidazoisoquinoline (B 11 A)
inotropic effects of, 299
structure of, 299
Berberine
inotropic effects of, 306
Bestatin
immunomodulation by, 152, 159, 162
Biomembranes
measurement of drug solubility in, 46–47
see also Membrane fluidity
Biphenyl
pharmacokinetics of, 85–100
structure of, 86
Birds
insecticide metabolism in, 20–21
Bleomycin
delivery systems for, 203–4
β-Blockers
delivery systems in study of, 224–25
modulated receptor hypothesis, 391
Blood hormone levels
gossypol effect on, 342–43
Blood vessels
developmental studies of smooth muscle reactivity, 69–76
Bradykinin
and vasodilation, 179, 181–82
Brain
vanadium in, 513–14
Brain enzyme receptor systems
non-equilibrium behavior of, 237–61
allosteric principle, 238–40
behavior of TOH & TPOH, 243
macroscopic dynamical complexity, 248–51
as multiple receptor ligand binding processes, 254–58
physiologic conditions and behavior of TOH & TPOH, 240–43
solvent entropy sequence, 258–61

statistical kinematics, 251–54
Bright's disease
and antiadrenergics, 105–17
Bromdeoxyuridine
delivery systems for, 217
p-Bromophenacylbromide (BPB)
on arterial relaxation, 187
Bufuralol
inotropic effects of, 288
Bupivicaine
modulated receptor hypothesis, 411
Buquineran (UK 14275)
inotropic effects of, 291, 297
structure of, 291
Buserelin
delivery systems in study of, 213
Butaperazine
plasma monitoring studies, 367
Butopamine
inotropic effects, 279, 287
Bux
metabolism of, 26
BW 755 C
and vasodilation, 191

C

Cadmium
delivery system for, 222–23
neurotoxicity of, 431, 443
Calcium
and arterial relaxation, 187–88
at neuronal muscarinic receptor, 122, 126, 128–36, 138–39
Calcium channel blockers
modulated receptor hypothesis, 387–88, 405–9
activated/inactivated affinities, 406–7
dihydropyridines, 407–8
site of action, 408–9
use-dependence, 405
voltage-dependence of recovery, 406
Calcium ionophores
inotropic effects of, 308–9
Ca^{++} + Mg^{++}ATPase
vanadium effect on, 507–9, 511–12
Calmodulin
regulatory properties of, 237
and vanadium, 508
Cannabinoids
on membrane fluidity, 50–51
Carbachol
and muscarinic receptor, 125, 131, 133, 136–37
and vasodilation, 178
Carbamate insecticides
metabolism of, 26, 28
Carbamylcholine
and vasodilation, 177
Carbazeran (UK 31557)
inotropic effects of, 292
structure of, 292
Carbofuran
metabolism of, 27
Carbon disulfide
neurotoxicity of, 431
Cardioactive bipyridines
inotropic effects of, 293–95
mechanism of action, 295
Cassaine
inotropic effects of, 299
Cassava
cyanide intoxication from, 452, 460–61
Catalase
and cyanide intoxication, 458
Catecholamine
vanadium effect on, 506, 513
Chemotactic factors
and immunity, 149
Children
plasma neuroleptic concentrations in, 379–80
α-Chloralose
on membrane fluidity, 49
Chlorambucil
immunomodulation by, 152
p-Chloramphetamine
delivery systems in study of, 223
Chlordane
metabolism of, 23, 25
neurotoxicity of, 428
Chlordecone
neurotoxicity of, 428, 431, 436, 441, 445
Chlordimeform
neurotoxicity of, 443
Chlorfenvinphos
metabolism of, 34
Chlorhydrins
in insecticide metabolism, 25
Chlorinated dibenzofurans
pharmacokinetics of, 86
Chlorisondamine
developmental studies of, 67
Chloroform
on membrane fluidity, 48–49
p-Chloromercuribenzoate
inotropic effects of, 299, 301
Chlorprocaine
modulated receptor hypothesis, 404
Chlorpromazine
cyanide antagonism by, 466
inotropic effects of, 299
on membrane fluidity, 50–51
plasma monitoring studies, 362–73
anticholinergic interaction, 369–73
chronicity of disease, 366–69
fluid concentration/clinical effect, 362–65
radioreceptor assay, 365–66
and vanadium, 506
Cholera toxin
inotropic effects of, 307
Cholesterol
on membrane fluidity, 52, 59
Chromosomes
gossypol effects on, 341
Chronotropic effect
separation from inotropic, 276–77
Cilostamide (OPC 3689)
inotropic effects of, 291, 297–98
structure of, 291
Circadian rhythms
and drug delivery systems, 221–22
Citrate
and vanadium, 506
Clonidine
delivery systems for, 200, 223–24
on renal hypertension, 106–8, 117
Clorgyline
delivery systems in study of, 213
Cobalt
cyanide antagonism by, 462, 466–67, 472–73
at muscarinic receptor, 127
Cobalt chloride
cyanide antagonism by, 467
Cobalt histidine
cyanide antagonism by, 467
Cocaine
and dopamine, 280
modulated receptor hypothesis, 388
Coenzyme Q_{10}
inotropic effect of, 306–8
Cohn Fraction II
immunomodulation by, 152
Collagen
developmental studies in blood vessels, 70–71
Collagen synthesizing factor
and immunity, 149
Compound 48/80
and histamine storage, 9–10
Comprehensive psychopathological rating scale (CPRS)

to study neuroleptics, 363
Copper
and cyanide intoxication, 458
Copper sulfate
neurotoxicological considerations of, 443
Corn
cyanide intoxication from, 453
Corticotropin-releasing factor
non-equilibrium behavior of, 259–60
Corynebacterium parvum
immunomodulation by, 152, 161–62
Cotton
antifertility factor from, 329
see also Gossypol
Coumarin derivative
teratogenic effects of, 488, 490
Crunetrin
metabolism of, 31
Cyanide intoxication, 451–81
antagonism of, 462–70
biotransformation, 462–64
chemical binding, 464–68
oxygen in, 468–70
dedication, 452
introduction, 451
methodology, 454–57
detection and concentration estimation, 455–57
tissue selection and storage, 454–55
potential sources of, 452–54
human-related, 453–54
natural causes, 452–53
toxic manifestations and mechanism of, 457–62
treatment, 470–73
cobalt, 472–73
methemoglobin-sulfur-sulfanes-oxygen, 471–72
supportive treatment, 471
Cyanogenic glycosides
natural causes of, 452–53
Cyanohydrin
in cyanide antagonism, 467–68
Cyclic adenosine monophosphate (cAMP)
at muscarinic receptor, 125, 133
positive inotropic role of, 275–77, 281, 283, 289, 292
and vanadium, 510
Cyclic AMP analogs
inotropic effects of, 292
structure of, 292
Cyclic guanosine monophosphate (cGMP)
and muscarinic receptor, 123, 125, 128–34, 136–39
scheme of, 136
and vasodilation, 193
Cyclic nucleotides
at muscarinic receptor, 132–40
Cyclodienes
metabolism, 24
in birds, 20–21
Cypermethrin
metabolism of, 26, 33
Cytochrome oxidase
and cyanide intoxication, 457–59, 468–70
Cytochrome P-448
in PCB metabolism, 89
Cytochrome P-450
in metabolism of insecticides, 22–29
aliphatic hydroxylation, 26–27
dealkylation, 28–29
desulfuration and ester cleavage, 22–23
epoxidation and aromatic hydroxylation, 23–26
heterocyclic ring hydroxylation, 27–28
in PCB pharmacokinetics, 89
Cytomegalovirus
teratogenic effect of, 495
Cytotoxic drugs
immunomodulation by, 152

D

D 600
modulated receptor hypothesis, 406–9
D 890
modulated receptor hypothesis, 408
D 4975
inotropic effects of, 288–89
DDT
metabolism of, 26
neurotoxicity of, 428, 431
Deamino-8-D-arginine vasopressin
delivery systems for, 203
Decamethrin
metabolism of, 26
Delivery systems
rate-controlled, 199–236
circadian and other patterns, 221–22
conclusion, 226
environmental studies, 199
fetal, 217
injection-infusion comparison protocol, 203–7
intra-arterial infusion, 220–21
introduction, 199–203
labelling studies, 217–18
modulation of hormonal levels, 212–17
new animal models, 224–26
pharmacokinetics, 223
rebound phenomena with antihypertensives, 223–24
stress of dosing, 218–20
tissue microperfusion, 207–10
tolerance and dependence, 211–12
Deltamethrin
metabolism of, 33
Dependence
delivery systems in study of, 211–12
on drugs and alcohol
reviews of, 531–32
Dermorphins
tolerance studies, 212
Desmethylimipramine
and dopamine, 280
and neuroleptics, 369
Developmental pharmacology
vascular smooth muscle reactivity, 65–83
adrenal medulla, 68–69
adrenergic nervous ontogeny, 66–68
blood vessels, 69–76
clinical correlates, 76–79
scope, 65–66
species variation, 66
Diabetes mellitus
teratogenic effects of, 495
Dialyzable leukocyte extract (DLE)
and immunity, 149, 156–59
1,4-Diazabicyclo(2,2,2)octane
on insecticide metabolism, 25
Diazinon
metabolism in fish, 20
Diazoxide
on arterial relaxation, 185
Dibenamine
and vasodilation, 179
Dicobalt ethylenediaminetetraacetic acid (Co_2EDTA)
cyanide antagonism by, 467, 472–73
Dieldrin
metabolism of, 24, 27, 34–35
neurotoxicity of, 428
Diethylaminoethyl-D (DEAE-D)
immunomodulation by, 154

Diethyl ether
on membrane fluidity, 49
Diethylstilbestrol
teratogenic effects of, 488, 490–91
Diflubenzuron
metabolism of, 33
1,3-Dihydro-4-methyl-(5-[4-(methylthio)benzoyl]-2H-imidazol-2-one (MDL 17043)
inotropic effects of, 291, 295–96
1,6-Dihydro-2-methyl-6-oxo-[3,4-bipyridine]-5-carbonitrile
see Milrinone
Dihydropyridine
modulated receptor hypothesis, 407–8
1,25-Dihydroxycholecalciferol
and vanadium, 514
Dihydroxyphenylalanine (DOPA)
in brain enzyme receptor systems, 240
Dillapiole
on insecticide metabolism, 36
Diltiazem
modulated receptor hypothesis, 405–7, 410
6,7-Dimethoxy-1-[3(trifluoromethyl)phenyl]-3,4-dihydroisoquinoline HCl (USV 2776)
inotropic effects of, 291
structure of, 291
4-Dimethylaminophenol (DMAP)
cyanide antagonism by, 464–65, 472
Dimyristoylphosphatidylcholine
as membrane solvent, 46
Dinitrophenol (DNP)
at muscarinic receptor, 128
Diphenhydramine
modulated receptor hypothesis, 388
1,6-Diphenyl-1,3,5-hexatriene (DPH)
to study membrane fluidity, 53–55
Diphenylhydantoin
teratogenic effects of, 488, 491
Disopyramide
modulated receptor hypothesis, 391, 398, 409
DNA synthesis
gossypol effect on, 350
Dobutamine
inotropic effects of, 276–77, 279, 282–84
Dopamine
delivery systems for, 200
inotropic effects of, 276–89
on membrane fluidity, 44, 47
Dopamine analog (E)
inotropic effects of, 290
structure of, 290
Doxaminol (BM 10 1088)
inotropic effects of, 287–88
Doxorubicin
inotropic effect of, 300
structure of, 300
5- & 12-Doxylstearic acid
and membrane fluidity, 52
Droperidol
modulated receptor hypothesis, 391, 398
Dynein ATPases
and vanadium, 509
Dynorphin
non-equilibrium behavior of, 259

E

Ear
vanadium in, 513
EDTA
and vanadium, 506
Eggs
PCBs in, 91–92
5,8,11,14-Eicosatetranoic acid (ETYA)
on arterial relaxation, 186, 191
at muscarinic receptor, 136–137
Elastin
developmental studies in blood vessels, 70
Electron Spin Resonance (ESR)
to study membrane fluidity, 44, 48–53
Eledoisin
on vasodilation, 181
Encainide
modulated receptor hypothesis, 391, 409
Endorphin
reviews of, 528
β-Endorphin
non-equilibrium behavior of, 259
receptor, 529
Endothelium
and vasodilation, 175–94
arterial relaxation by ACh, 176–79
arterial relaxation by other drugs, 180–85
conclusions, 194
endothelium-derived relaxing factors, 190–92
inhibitors of endothelium-dependent relaxation, 185–89
introduction, 175
mechanism of EDRF relaxation, 192–94
relaxation of resistance vessels and veins, 189–90
Endothelium-Derived Relaxing Factor (EDRF)
and vasodilation, 179, 188, 190–92
characteristics of, 190–92
mechanisms of action, 192–94
Enkephalin
cross-tolerance with morphine, 211–12
Enterocolitis, necrotizing
developmental pharmacology of, 78–79
Environment
teratogens in, 483
Enzyme proteins
non-equilibrium behavior of, 237–58
Enzymes
and cyanide intoxication, 458
monooxygenases
in metabolism of insecticides, 19–42
Ephedrine
inotropic effects of, 277
Epinephrine
developmental studies of, 75
inotropic effects of, 276, 280
Erythrocyte concentration
and neuroleptic effectiveness, 364
Erythrophleum alkaloids
inotropic effects of, 299, 301
Estradiol
rate-controlled delivery system for, 210, 212, 216
Estrogens
delivery systems in assay of, 216
teratogenic effects of, 490–91
Ethacrynic acid
inotropic effects of, 300
structure of, 300
Ethanol
on membrane fluidity, 52–55, 57
chronic effects of, 57–58
rate-controlled delivery systems for, 212
17-α-Ethinyl-17-OH-5(10)estren-3-one (Enovid-R)
teratogenic effects of, 493

17-α-Ethinyl-19-nortestosterone (Norethandrone)
teratogenic effects of, 493
17-α-Ethinyl-testosterone
teratogenic effects of, 492
Ethmozin
modulated receptor hypothesis, 391, 409
Ethylene vinyl acetate (EVA) copolymer pellets
as rate-controlled delivery system, 200, 210
N-Ethylmaleimide
inotropic effects of, 299, 301
at muscarinic receptor, 126
structure of, 299
Etorphine
non-equilibrium behavior of, 255
Eye
vanadium effect on, 513

F

Facteur thymique serique
immunomodulation by, 152, 162
FAD-containing monooxygenase
in insecticide metabolism, 30–32
desulfuration, 31–32
reaction sequence, 22
sulfoxidation, 30–31
Fetal alcohol syndrome
description of, 487
Fetus
drug delivery in, 217
growth retardation studies, 226
persistent fetal circulation, 66–67
Fish
insecticide metabolism in, 20
Flecainide
modulation receptor hypothesis, 391, 409
Fluorescence polarization
to study membrane fluidity, 53–55
Fluphenazine
plasma monitoring studies of, 376–80
age/concentration, 379–80
megadoses, 379
Fluphenthixol
and neuroleptics, 370
Fonofos
metabolism of, 31–32
Forskolin
inotropic effects of, 305–7
structure, 306
Frapadil
inotropic effects of, 307
Fruit pits
cyanide intoxication from, 453
L-Fucose
as immunomodulator, 159

G

GABA
on membrane fluidity, 44
Gastrin
and gastric secretion, 3–4, 12–13
Genetic programming
and teratogenesis, 483–84
Gentamicin
delivery systems in study of, 223
γ-Globulin
immunomodulation by, 152
Glucagon
delivery systems in study of, 214
inotropic effects of, 306
Glutathione
and vanadium, 506
Glyceryl trinitrite
in arterial relaxation, 177, 188
Gonadotropin-releasing hormone (GnRH)
delivery systems to study, 212–13, 215, 221
Gossypol
antifertility effects of, 329–51
chemistry, 330–31
clinical trials, 342–45
conclusions, 351
endocrine effects, 340–42
genetic effects, 336–40
hypokalemic paralysis, 346–49
introduction, 329–30
metabolism of, 332–34
site and mechanism of action, 349–51
toxicity, 334–36
Granulocytic migration inhibitory factor (LIF)
and immunity, 149
Grayanotoxins
inotropic effects of, 302
structure of, 303
Growth hormone
delivery systems in study of, 213–14, 218
Growth inhibitory factors
and immunity, 149
Guanabenz
on renal hypertension, 107–8, 117
Guanfacine
delivery systems in rebound study, 223
Guanidine
non-equilibrium binding of, 256
Guanosine
on insecticide metabolism, 25
Guanosine triphosphate (GTP)
at muscarinic receptor, 123, 125
Guanylate cyclase
at neuronal muscarinic receptor, 122, 135, 137
Guanyl nucleotides
at muscarinic receptor, 124–25

H

Haloperidol
delivery systems in study of, 213, 223
non-equilibrium binding of, 255
plasma monitoring studies of, 373–76
assay methods, 373–74
dose-level correlation, 374
response-level correlation, 374–76
Halothane
on membrane fluidity, 48–49, 58
Heart
ontogeny of vascular smooth muscle in, 67–68
vanadium in, 511
Heavy metals
neurotoxicity of, 431
Hemodynamics
β-blockers on, 112
Hemoglobin
on arterial relaxation, 189
Heparin
by EVA pellets, 210
Heptachlor
metabolism of, 25
Heptanol
on membrane fluidity, 51
Heroin
reviews of, 532
Hexane
neurotoxicity of, 431
Hexanol
on membrane fluidity, 51
Histamine
in anaphylaxis, 6
delivery systems in study of, 224
inotropic effects of, 307

mast cell storage and release of, 9–12
at muscarinic receptor, 136–38
and vasodilation, 178, 182–83, 192
$H^+ + K^+$ ATPase
vanadium effects on, 509
Hormones
insect
metabolism of, 33
rate-controlled modulation of levels of, 212–17
renal vasoactive
and hypertension, 114
Horseradish peroxidase
and cyanide intoxication, 458
Human growth hormone (hGH)
delivery systems for, 206
Hydralazine
on arterial relaxation, 185
Hydrophobic effects
of brain enzyme receptor systems, 238–40
Hydroquinone
on arterial relaxation, 188
Hydroxycobalamin
cyanide antagonism by, 467, 472–73
6-Hydroxydopamine (6-OHDA)
rate-controlled delivery system for, 207–8, 211
9-Hydroxyelliptisine
inotropic effects of, 290
structure of, 290
2- and 4-Hydroxyestradiol
delivery systems in study of, 216
3α-Hydroxy-5α-pregnane-11,20-dione
on membrane fluidity, 50
Hypertension
renal function in
antiadrenergic, antihypertensive drugs in, 105–20
Hypokalemic paralysis
from gossypol, 346–49
Hypothalamus
gossypol effects on, 340

I

Ibopamine
inotropic effects of, 279, 286–87
ICI 118587
inotropic effects of, 280, 286
structure, 280
Imidazole
inotropic effects of, 307
Imipramine
modulated receptor hypothesis, 391, 409
and neuroleptics, 369
and vanadium, 506, 513
Immunomodulators, 147–69
table of, 152
Immunostimulation, 147–74
adoptive transfer of immunity, 154–59
DLE, 156–59
immune RNA, 154–56
chemically synthesized immunomodulators, 165–68
levamisol, 165–66
maleic anhydride divinyl ether, 166
methisoprinol, 166–67
NPT 15392, 168
tuftsin, 168
conclusion, 168–69
introduction, 147–51
nonantigen-specific, 179–65
BCG, 159–61
bestatin, 162
corynebacterium parvum, 161–62
interferon, 163–65
thymic hormone, 162–63
specific active immunotherapy, 151–54
Implantable device
for drug administration, 199–226
Indalprine
and vanadium, 513
Indomethacin
delivery systems for, 200
and vasodilation, 181, 184
Induction
of monooxygenase system, 34–35
insecticides as inducers, 34–35
Information retrieval
current state of, 525–26
Inocor
inotropic effect of, 294
Inosine
inotropic effects of, 306
Inotropics, positive
see Positive inotropics
Insect growth regulators
metabolism of, 33
Insecticide metabolism
monooxygenase enzymes in, 19–42
cytochrome P 450 reactions, 22–29
FAD-containing monooxygenase systems, 30–32
induction effect of, 34
inhibition, 35–36
insecticides as inducers, 34–35
introduction, 19–20
monooxygenase systems, 20–22
newer insecticides, 32–33
prostaglandin biosynthesis, 29–30
summary and conclusion, 36–37
Insecticides
neurotoxicity of, 428, 431, 435–36, 441, 443, 445
Insulin
delivery systems in study of, 214–15, 226
Interferon
gossypol induction of, 351
and immunity, 149, 152, 163–65
Interleukin 2 (TCGF)
and immunity, 149
Intra-arterial infusion
chronic methodology, 220–21
Intraventricular hemorrhage
developmental pharmacology of, 77–88
Iodides
teratogenic effects of, 489, 494–95
Ionophore antibiotics
inotropic effects of, 306
Isobutylmethylxanthine
at muscarinic receptor, 137
Isodrin
on insecticide metabolism, 25
Isoproterenol (INE)
α activation by, 276–78, 283
and arterial relaxation, 177
delivery systems in study of, 213
developmental studies of, 67, 72, 75
Isosafrole
on insecticide metabolism, 35
IUPHAR
history of formation of, 18

J

Journals
new, 525–26
Juvenile hormones
metabolism of, 33, 35

K

Kadethrin
metabolism of, 26

Kallikrein-Kinin system
and hypertension, 114, 117
Kassanin
on arterial relaxation, 181
Kepone
metabolism of, 34–35
Ketamine
on membrane fluidity, 49
Kidney
hypertension role of
antiadrenergic and antihypertensive drugs, 105–20
vanadium in, 512

L

Labelling
delivery systems for, 217–18
Laetrile
cyanide poisoning from, 454
Landrin
metabolism of, 26
Lanthanides
at muscarinic receptor, 134
Lasalocid (X 537 A)
inotropic effects of, 306
Lead
neurotoxicity of, 427, 429–31, 436, 442
Lead acetate
neurotoxicity of, 436
Learning
neurotoxicity considerations of, 440–42
Lecithin
in membranes, 46, 48
Lecithinase A
see Phospholipase A
Lentinan
as immunomodulator, 159, 162
Leu-enkephalin
non-equilibrium behavior of, 259, 261
Levamisole
immunomodulation by, 152, 165–66
Levodopa
inotropic effects of, 279
Leydig cell
gossypol effects on, 340
Lidocaine
on membrane fluidity, 49
modulated receptor hypothesis, 388–92, 396–400, 402–3, 409–11
Lima beans
cyanide intoxication from, 453
Lindane
metabolism of, 25, 29, 35
Linseed
cyanide intoxication from, 453
Lipoxygenase (LPO)
at muscarinic receptor, 137
Lithium
on arterial relaxation, 188
Lithium bromide
non-equilibrium behavior of, 256
Lorcainide
modulated receptor hypothesis, 39
Luteinizing hormone (LH)
delivery systems in study of, 213–14, 221
Lymphocytotoxin
and immunity, 149
Lymphokines
and immunity, 148–69
table, 149
Lynestrenole
as immunomodulator, 159
Lysergic acid diethylamide (LSD)
delivery system for, 208

M

Macromolecular stability
of brain enzyme receptors, 238–40
Macrophage activating factor
and immunity, 149
Macrophage migration inhibitory factor (MIF)
and immunity, 149
Macroscopic dynamical complexity
in enzyme proteins, 248–51
Maleic anhydride divinyl ether (MVE)
immunonodulation by, 152, 166
Manganese
at muscarinic receptor, 123, 127, 131, 134, 136–37, 139
neurotoxicity of, 431
Manioc
cyanide intoxication from, 452
Melanotropins
delivery systems in study of, 218
Membrane fluidity, 43–64
chronic administration of membrane-disordering drugs, 57–58
entry of drugs into membranes, 45–47
biomembranes, 46–47
bulk solvents, 45–46
model membranes, 46
introduction, 43–45
meaning of membrane fluidity, 44–45
in vitro measurements, 47–56
electron spin resonance, 48–53
fluorescence polarization, 53–55
NMR, 47–48
phase transitions, 55–56
summary, 59
Memory
and muscarinic receptor, 122
neurotoxicological aspects, 440–42
Mercury
neurotoxicity of, 431, 434, 442
Mesudipine
modulated receptor hypothesis, 407
Metabolism
of insecticides
role of monooxygenases in, 19–42
of polychlorinated biphenyls, 88–90
Metaproterenol
inotropic effects of, 277
Methacholine
and vasodilation, 177–80
Methadone
in heroin addiction review, 532
Methemoglobin-sulfur
cyanide antagonism by, 47–72
Methidathion
metabolism of, 31
Methimazole
teratogenic effects of, 495
Methiocarb
metabolism of, 31
Methisoprinol (ISO)
immunomodulation by, 152, 166–67
Methotrexate
teratogenic effects of, 487–88
Methoxamine
α-activation by, 276
cyanide antagonism by, 466
Methoxyflurane
on membrane fluidity, 49, 55
α-Methyldopa
delivery systems in rebound study, 223–24
on renal hypertension, 107–8, 117
Methylene blue
on arterial relaxation, 188
cyanide antagonism by, 465
and vanadium, 506

Methyl mercury
neurotoxicity of, 428–29, 431, 436, 443
teratogenic effects of, 488, 491–92
Methyltestosterone
teratogenic effects of, 487
Methylxanthine
inotropic effects of, 292–93
Metoprolol
on renal hypertension, 110–14, 117
Mexiletine
modulated receptor hypothesis, 391–92, 398, 409, 411
Milk
PCBs in, 91
Millet
cyanide intoxication from, 453
Milrinone (Win 47203)
inotropic effects of, 291, 295
Minoxidil
on arterial relaxation, 185
Mirex
metabolism of, 34
Mitogenic factors for lymphocytes
and immunity, 149
Modulated receptor hypothesis of antiarrhythmics, 387–412
Monoamine oxidase inhibitors
and dopamine, 280
Monoclonal antibodies
immunomodulation by, 152
Monooxygenase enzymes
in metabolism of insecticides, 19–42
cytochrome P 450 reactions, 22–29
FAD-containing monooxygenase systems, 30–32
induction effect of, 34
inhibition, 35–36
insecticides as inducers, 34–35
introduction, 19–20
monooxygenase systems, 20–22
newer insecticides, 32–33
prostaglandin biosynthesis, 29–30
summary and conclusion, 36–37
Monooxygenase systems
mechanism of action of, 20–22
Monosodium salicylate
neurotoxicity of, 436
Morphine
tolerance studies, 211–12
Muramyl dipeptide (MDP)
immunomodulation by, 160
Muscarinic receptor
and vasodilation, 177–78
see also Neuronal muscarinic receptors, 121–46
Muscle, smooth
developmental changes in vascular reactivity, 65–83
Myoglobin
and cyanide intoxication, 458
Myosin ATPase
and vanadium, 509
Myristicin
on insecticide metabolism, 36

N

Nadolol
on renal hypertension, 110–11, 113–115, 117
NADPH
and vanadium, 506
$Na^+ + K^+$ ATPase
and gossypol, 347–49
inhibitors of, 298–309
structures of, 299–300
vanadium effect on, 505–7, 510–13
Naltrexone
delivery systems in study of, 213
Naphthalene
metabolism, 26
in birds, 21
N1E-115 cells
to study neuronal muscarinic receptor, 122–40
Neuraminidase
immunomodulation by, 152–53
Neurobehavioral toxicity
assessment of, 425–46
examples of testing methods, 436–44
introduction, 425–30
problems and research needs, 444–46
test selection, 430–36
Neuroleptics
concentrations/clinical response, 361–80
chlorpromazine, 362–73
conclusion, 380
fluphenazine, 376–80
haloperidol, 373–76
introduction, 361–62
on membrane fluidity, 44
at muscarinic receptor, 123
Neuronal muscarinic receptors, 121–46
biochemical nature of, 123–27
introduction, 121–23
molecular consequences of receptor activation, 128–40
biochemical responses, 130–32
changes in cell electrical properties, 128–30
cyclic nucleotide response, 132–40
Neuropsychobiology
statistical kinematics of nonequilibrium steady-states, 251–54
Neurotoxicants
examples of, 427–30
Newborn
persistent fetal circulation studies, 66–67
Nickel
at muscarinic receptor, 127
Nicotine
developmental studies of, 67
metabolism of, 27–28, 34
Nifedipine
modulated receptor hypothesis, 405, 407–8
Nimodipine
modulated receptor hypothesis, 407
Nisoldipine
modulated receptor hypothesis, 407
Nitrate reductase
and cyanide intoxication, 458
Nitrendipine
modulated receptor hypothesis, 406–7
Nitriles
chronic delivery system to study, 222
Nitrite reductase
and cyanide intoxication, 458
Nitrites
cyanide antagonism by, 464–66
Nitroglycerin
on arterial relaxation, 185
delivery systems for, 200
Nitroprusside
on arterial relaxation, 185, 188, 192
delivery systems for, 200
Non-equilibrium behavior
of brain enzyme receptor systems, 237–58
as multiple receptor ligand-binding process, 254–58
Nordihydroguiaretic acid (NDGA)
on arterial relaxation, 187, 191

at muscarinic receptor, 136–37
Norepinephrine
on cortical neuronal plasticity, 207–8
developmental studies of, 67–69, 74–76
inotropic effects of, 276–78, 280, 282–83, 290
and vanadium, 511
and vasodilation, 178–79
NPT 15392
immunomodulation by, 152, 168
NPT 16416
immunomodulation by, 152, 165
Nuclear magnetic resonance (NMR)
to study membrane fluidity, 44, 47–48

O

Octacholecystokin
on arterial relaxation, 181
Octanol
in membranes, 46, 51
Opiate receptors
chronic delivery system in study of, 211–12
Opiopeptins
reviews of, 528–30
Organochlorine insecticides
neurotoxicity of, 428, 431, 435–36, 441, 443, 445
Organoleads
neurotoxicity of, 429–436
Organometals
neurotoxicity of, 431
Organophosphate esters
neurotoxicity of, 431
Organophosphorus (OP) insecticides
metabolism of, 23, 27, 31, 34
Ornithine decarboxylase
developmental studies of, 67–68
Orphenadrine
and neuroleptics, 369–70
Osmotic pumps
for rate-controlled drug delivery, 199–200, 212
Osteoclast activating factor
and immunity, 149
Ouabain
and vanadium, 507
Oxazolidine-2,4-diones
teratogenic effects of, 489, 492
DL-2-Oxo-3-(2-mercapto-ethyl)-5-phenylimidazolidine
as immunomodulator, 165
Oxotremorine
at muscarinic receptor, 133
Oxygen
cyanide antagonism of, 468–72
Oxyprenolol
on renal hypertension, 112

P

Papaverine
and arterial relaxation, 177
modulated receptor hypothesis, 405
Paraoxon
metabolism of, 22–23, 36
Parathion
metabolism of, 21–23, 31, 35–36
in birds, 21
Parathyroid hormone (PTH)
delivery systems for, 206, 216
and vanadium, 514
PCBs (Polychlorinated biphenyls)
pharmacokinetics of, 85–103
Pentobarbital
in membranes, 46, 50
rate-controlled delivery system for, 211
Pentylenetetrazol
neurotoxicity of, 440
Peptides
and vasodilation, 181
Permethrin
metabolism of, 26
Pharmacokinetics
of PCBs, 85–103
introduction, 85–92
modeling, 88, 92–99
summary, 99–100
Phase transitions
to study membrane fluidity, 55–56
Phencyclidine
tolerance studies, 212
Phenobarbital
delivery system for study of, 223
Phenols
in membranes, 46
Phenoxybenzamine
cyanide antagonism by, 466
developmental studies with, 75
and renal hypertension, 106, 108–9
Phentolamine
developmental studies of, 74
and renal hypertension, 106
Phenylephrine
α activation by, 276
Phenyl fonofos
metabolism of, 31
Phenytoin
modulated receptor hypothesis, 387, 391, 409
at muscarinic receptor, 127
Phosphatidic acid (PA)
at muscarinic receptor, 127, 130–32, 135–36
Phosphatidylinositol (PI)
at muscarinic receptor, 125, 127, 130–32, 138–40
Phosphatidylserine
at muscarinic receptor, 127
Phosphodiesterase (PDE) inhibitors
inotropic effects of, 289–98
Phospholipase A
mast cell role of, 10
at muscarinic receptor, 127
Phospholipase C (PLC)
at muscarinic receptor, 132
Phospholipid methyltransferases
and membrane fluidity, 55
Phospholipids
metabolism of
at muscarinic receptor, 130–32
Phospholipids, acidic
at muscarinic receptor, 127
Photoaldrin
Phthalazinol (EG 626)
inotropic effect of, 292, 298
structure of, 292
Physalaemin
on arterial relaxation, 181
Physostigmine
neurotoxicity of, 443
Picibanil
as immunomodulator, 159
Pilocarpine
delivery system for, 200
Pindolol
on renal hypertension, 110–12, 114
Piperonyl butoxide
on insecticide metabolism, 35
Pirbuterol
inotropic effects of, 279, 286
Pirenzepine
at muscarinic receptor, 126
Pituitary
gossypol effects on, 340
Plasma volume
β-blockers on, 112–13
Polychlorinated biphenyls (PCBs)
pharmacokinetics, 85–103
introduction, 85–92
modeling, 92–99

summary, 100
teratogenic effects of, 489, 492
Polynucleotides
as immunomodulators, 159
Polypeptides
brain
solvent entropy sequence, 258–61
Polysiloxane (Silastic)
as delivery system, 200, 212–13
Positive inotropics, 275–328
adrenergics, 275–78
dopamine, 278–89
inhibitors of Na+ K+ ATPase, 298–309
introduction, 275
phosphodiesterase inhibitors, 289–90, 292–98
Potassium (K)
and antiarrhythmics, 402
on arterial relaxation, 188
and gossypol, 346–49
and neuronal muscarinic receptor, 121–22, 125, 128–29, 135, 137
Prazosin
on renal hypertension, 107, 109
Precocenes
metabolism of, 33
Prednisone bisguanyl hydrazone (PBGH)
inotropic effects of, 299
structure of, 299
Prenalterol
inotropic effects of, 276–77, 279, 285–86
structure, 279
Prenylamine
modulated receptor hypothesis, 391, 398, 409
Procainamide
modulated receptor hypothesis, 388, 391–93, 396, 398, 409
Procaine
modulated receptor hypothesis, 404
Procyclidine
and neuroleptics, 370
Profenofos
metabolism of, 30
Progesterone
delivery systems for, 200
Progestins
teratogenic effects of, 489, 492–93
Prolactin
delivery systems in study of, 213, 217
inotropic effect of, 290
Propafenone
modulated receptor hypothesis, 391–92, 409
Propantheline
and neuroleptics, 369
Propoxur
metabolism of, 26, 35
Propranolol
delivery systems for, 201–2, 213, 223–24
developmental studies of, 73
on membrane fluidity, 50
modulated receptor hypothesis, 391, 409
on renal hypertension, 110–17
Propylthiouracil
teratogenic effects of, 495
Prostaglandin biosynthesis
and insecticide metabolism, 29–30
Prostaglandin E_1
at muscarinic receptor, 125, 138, 140
Prostaglandin E_2
and vanadium, 514
Prostaglandin $F_{2\alpha}$
on vasodilation, 178
Prostaglandins
in "first-breath" vasodilation, 77
and gossypol, 350
non-involvement in arterial relaxation, 176–77, 184
Protamine
rate-controlled delivery system for, 210
Psychotropic drugs
on brain non-equilibrium, 254
Pyramet
metabolism of, 26
Pyrethroids
metabolism of, 27, 32–33, 36

Q

Quinacrine
on arterial relaxation, 186
and inotropism, 278
Quinidine
modulated receptor hypothesis, 387–92, 396–99, 401–2, 409–11
Quinonoid dihydropterin reductase (QDPR)
on brain enzyme receptor non-equilibrium, 241–42
[^{3}H]-Quinuclidinyl benzilate (^{3}H-QNB)
at muscarinic receptor, 126–27
QX-314
modulated receptor hypothesis, 392

R

Radiation
teratogenic effects of, 489, 493
Radioiodine
teratogenic effects of, 489, 494
Radioreceptor assay
for plasma levels of neuroleptics, 365–66
Rate-controlled delivery systems, 199–236
circadian and other patterns, 221–22
conclusion, 226
environmental studies, 222–23
fetal, 217
injection-infusion comparison protocol, 203–7
intra-arterial infusion, 220–21
labelling studies, 217–18
modulation of hormone levels, 212–17
rebound phenomena with antihypertensives, 223–24
stress of dosing, 218–20
tissue microperfusion, 207–10
tolerance and dependence, 211–12
RE-5365
metabolism of, 27
RE-11775
metabolism of, 27
Receptors
brain enzyme
non-equilibrium behavior, 237–58
modulated receptor of antiarrhythmics, 387–412
regulation of
delivery systems in study of, 212–13
Receptors, neuronal muscarinic, 121–46
biochemical nature of, 123–27
introduction, 121–23
molecular consequences of receptor activation, 128–40
biochemical responses, 130–32
changes in cell electrical properties, 128–30
cyclic nucleotide response, 132–40
Renin-angiotensin system
and hypertension, 114

Reserpine
and dopamine, 280
inotropic effects of, 301
Resistance vessels
endothelial cells in relaxation of, 189–90
Review
of reviews, 525–33
Rhodanese
cyanide antagonism by, 462–63, 469
Ribulose diphosphate carboxylase
cyanide intoxication, 458
RNA
immunomodulation by, 152, 154–56
RO 363
inotropic effects of, 280, 288
structure, 280
Rocornal
inotropic effect of, 292
Ross-Nelson osmotic pump
development of, 199–200
Rotenone
metabolism of, 29
Rubella
teratogenic effect of, 495
Rubidium chloride
inotropic effect of, 300–2

S

Safrole
on insecticide metabolism, 35
Salbutamol
inotropic effects, 279, 287
Sanguinarine
inotropic effects of, 299
structure of, 299
Schizophrenia, chronic
and neuroleptic plasma monitoring, 367, 375
Schizophyllan
as immunomodulator, 159
Scopolamine
delivery systems for, 200
Scorpion poison
inotropic effects of, 302–3
Sea anemone polypeptides
inotropic effects of, 302
Secretin
inotropic effects of, 306
Semen
gossypol effects on, 344
SEPHAR
history of, 16–18
Serotonin
developmental studies of, 74
and vasodilation, 178, 183
SKF 525 A
on insecticide metabolism, 22–25, 27–29
Skin permeability factor
and immunity, 149
Slow-reacting substance (SRS)
and histamine release, 9–10
SM-1213
as immunomodulator, 160
Smooth muscle
vanadium in, 510–11
Sodium azide
and arterial relaxation, 177, 192
Sodium barbital
rate-controlled delivery of, 211
Sodium channel blockers
modulated receptor hypothesis, 389–404
pH effects, 401–3
rested, activated, and inactivated blockade, 392–98
structure-activity, 403–4
use-dependent block, 389–92
voltage dependent, 398–401
Sodium cyanide
to study toxicity from environment, 222
Sodium fluoride
inotropic effects of, 306
Sodium fluoroacetate
inotropic effects of, 307
Sodium nitrite
and arterial relaxation, 177, 188
cyanide antagonism by, 462, 465–66
Sodium nitroprusside
and arterial relaxation, 177
and cyanide intoxication, 453–54
Sodium thiosulfate
cyanide antagonism by, 462, 466, 469
Solvent entropy
of brain receptor enzymes, 238–40
Solvents
entry into membranes, 45–46
neurotoxicity of, 427–28, 431–32, 436, 443
Somatostatin-25
non-equilibrium behavior of, 259
Species variation
in vascular smooth muscle development, 66
Spiperone
non-equilibrium studies, 255–56
Starvation
teratogenic effects of, 495
Steroid anesthetics
on membrane fluidity, 50
Stress
of dosing, 218–20
Strontium
at muscarinic receptor, 128
Structure-activity relationship
of antiarrhythmics, 403–5
Subacute sclerosing panencephalitis (SSPE)
immunotherapy of, 167
Substance P
delivery systems in study of, 218
and vasodilation, 181
Succinonitrile
cyanide intoxication from, 454
Sulfanes-oxygen
cyanide antagonism by, 471–72
Sulfhydryl inhibitors
inotropic effects of, 301–2
Sulfurtransferases
cyanide antagonism role of, 462–63
Sulmazole (Vardax, ARL 115 BS)
inotropic effects of, 291, 296–97
structure of, 291
Superoxide dismutase
on insecticide metabolism, 25
Sweet potato
cyanide intoxication from, 453
Syphilis
teratogenic effects of, 495

T

2,4,5-T
neurotoxicity of, 443
TA 064
inotropic effects of, 280, 288
structure, 280
Taurine
inotropic effects of, 307
T-cell growth factor (TCGF)
and immunity, 149
Teratogenesis
mechanisms of, 483–95
conclusion, 495
etiology, 484
human teratogens, 487–95
mechanisms, 483–87
table of, 486, 488–89
Terbutaline
inotropic effects of, 277

Testicular steroidogenesis
gossypol effects on, 340–42
Testosterone
delivery systems in study of, 213–14
teratogenic effects of, 487
Testosterone enanthate
teratogenic effects of, 487
Tetracaine
on membrane fluidity, 49
Tetracycline
teratogenic effects of, 489, 493–94
Tetraethylammonium
inotropic effect of, 303–4
Tetrahydro-β-carbolines
and ethanol, 212
Tetran
metabolism of, 32
Thalidomide
teratogenic effects of, 489, 494
Thallous ion
inotropic effect of, 300
Thalocythrin
metabolism of, 33
Theophylline
delivery systems for, 200, 223
Theophylline-dopamine derivative
inotropic effect of, 290
structure, 290
Therapeutic window
of neuroleptics, 375–76, 380
Thiabendazole
as immunomodulator, 159
Thiocyanate
cyanide intoxication from, 454
Thiofanox
metabolism of, 31
Thiopental
on membrane fluidity, 50
Thrombin
on arterial relaxation, 183
at muscarinic receptor, 136–37
Thymic hormones
immunomodulation by, 152, 162–63
^{3}H-Thymidine
delivery systems for, 217–18
Thymopoietin
immunomodulation by, 152, 162
Thymosin
immunomodulation by, 152, 162–63
Thymus
immunostimulation studies, 147–69
Thyroid
teratogenic effects of, 489, 494–95
Thyroid hormones
delivery systems in study of, 215
Thyrotropin-releasing hormone
non-equilibrium behavior of, 259
Tiloxine
as immunomodulator, 159
Tiron
on insecticide metabolism, 25
Tissue microperfusion
as rate-controlled microdelivery system, 207–10
Tobacco smoke
cyanide intoxication from, 453, 461
Tocainimide
modulated receptor hypothesis, 391, 398, 409
Tolazoline
as immunomodulator, 159
in persistent fetal circulation, 77
Tolerance
delivery systems in study of, 211–12
Toxaphene
metabolism of, 35
Toxicity
neurobehavioral assessment of, 425–46
Toxoplasmosis
teratogenic effect of, 495
Tralomethrin
metabolism of, 33
Transfer factor
immunomodulation by, 152, 156–59
Trapidil
inotropic effect of, 292
structure of, 292
Trapyrin
inotropic effect of, 292
2,4,6-Triaminopyrididine
inotropic effect of, 303–4
structure of, 303
Trichloroethanol
on membrane fluidity, 49
Tricyclic antidepressants
non-equilibrium behavior of, 254
Triethyl lead
neurotoxicity of, 429, 436
O, O, O-Tri(*p*-ethylphenyl)-phosphate (TPEP)
metabolism of, 27
Triethyl tin
neurotoxicity of, 436, 445
Trihexyphenidyl (THP)
and neuroleptics, 369–72
Tri-iodothyronine (T3)
delivery systems for, 206
Trimethaphan
developmental studies with, 75
Trimethyl tin
neurotoxicity of, 440
O,O,O-Tri-*o*-tolyphosphate (TOCP)
metabolism of, 27
Tryptophan (TRP)
in brain enzyme receptor systems, 240–43
Tryptophan hydroxylase (TPOH)
non-equilibrium behavior of, 237, 241–46, 248–51, 253
Tsumacide
metabolism of, 26
Tuftsin
immunomodulation by, 152, 168
Tyramine
developmental studies of, 67, 74–75
Tyrosine
non-equilibrium behavior of, 240
Tyrosine hydroxylase (TOH)
non-equilibrium behavior of, 237, 241–46, 248–51, 253

U

Ubiquinone
inotropic effects of, 306
UC-10854
metabolism of, 27
Urea
non-equilibrium binding of, 256
Urethane
on membrane fluidity, 49
Ustilmon
inotropic effect of, 292
structure of, 292
USV 2776
inotropic effects of, 298
Uvnäs, Börje
autobiographical chapter, 1–18

V

Valerate
in membranes, 46
Valproic acid
delivery systems for, 204–5
Vanadate
inotropic effect of, 300, 302

structure of, 300
Vanadium
and adenyl cyclase, 510
in brain, 513–14
Ca^{2+} + Mg^{2+}ATPase, 507–9
conclusions, 515
distribution of experimentally administered, 504–5
distribution of naturally occurring, 502–4
dynein ATPases, 509
eye and ear, 513
heart, 511–12
H^+K^+ ATPase, 509
introduction, 501–2
kidney, 512
miscellaneous, 514–15
Na^+ + K^+ ATPase, 505–7
nutritional importance, 505
smooth muscle, 510–11
Vanadocene chloride
on leukemia, 515
Vardax
inotropic effects of, 296–97
Vascular smooth muscle
role of endothelium in drug response, 175–94
Vasoactive intestinal peptide
inotropic effects of, 306
Vasodilation
and endothelium, 175–94
arterial relaxation by ACh, 176–79
arterial relaxation by other drugs, 180–85
conclusions, 194
endothelium-derived relaxing factors, 190–92
inhibitors of endothelium-dependent relaxation, 185–89
introduction, 175
mechanism of EDRF, 192–94
relaxation of resistance vessels and veins, 189–90
Vasopressin
delivery systems in study of, 214, 218
developmental pharmacology of, 74
Veins
endothelial cells and relaxation of, 190
Verapamil
modulated receptor hypothesis, 405–7, 410
Veratrum alkaloids
inotropic effects of, 302–3
structure of, 303
Virally associated neoantigens (VAA)
as immunomodulators, 153
Visnadin
inotropic effects of, 292
structure of, 292
Vitamin A
as immunomodulator, 159
Vitamin D
delivery systems for, 220, 226
Voltage dependence
of channel blockers
calcium, 406
sodium, 398–401

W

Warfarin
teratogenic effects of, 490
Water
cyanide intoxication from, 453

X

X-537-A
inotropic effects of, 309
at muscarinic receptor, 129, 131, 135
Xenogenization, viral
immunomodulation by, 152
Xylocaine
on membrane fluidity, 49

Y

Yeast cytochrome c peroxidase
and cyanide intoxication, 458

Z

Zinc
and cyanide intoxication, 458